scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1002976737 |
P356 | DOI | 10.1038/MODPATHOL.2016.88 |
P932 | PMC publication ID | 4967011 |
P698 | PubMed publication ID | 27174589 |
P50 | author | Jeremy A. Squire | Q39802515 |
Tamara L Lotan | Q62091289 | ||
Peter S Nelson | Q100440151 | ||
Lawrence D True | Q114402092 | ||
P2093 | author name string | Ladan Fazli | |
Martin Gleave | |||
Dean Troyer | |||
Ian M Thompson | |||
Wei Wei | |||
Daniel W Lin | |||
Ziding Feng | |||
Peter R Carroll | |||
James D Brooks | |||
Jesse K McKenney | |||
Jeffrey Simko | |||
Raymond Lance | |||
Antonio Hurtado-Coll | |||
Sarah T Hawley | |||
Olga Ludkovski | |||
Carlos L Morais | |||
Tamara Jamaspishvili | |||
Karen Lopez | |||
Liana B Guedes | |||
P2860 | cites work | Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer | Q24616117 |
The genomic complexity of primary human prostate cancer | Q24617949 | ||
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology | Q24632651 | ||
Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN | Q27005677 | ||
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. | Q27851411 | ||
Integrative clinical genomics of advanced prostate cancer | Q27853170 | ||
The mutational landscape of lethal castration-resistant prostate cancer | Q29614634 | ||
Integrative genomic profiling of human prostate cancer | Q29619905 | ||
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer | Q33723651 | ||
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation | Q34109986 | ||
Genetic markers associated with early cancer-specific mortality following prostatectomy | Q34340799 | ||
Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer | Q35234584 | ||
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. | Q35540013 | ||
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy | Q36610246 | ||
A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer | Q36887707 | ||
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. | Q36959119 | ||
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression | Q37383459 | ||
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray | Q38066715 | ||
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity | Q38400993 | ||
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients | Q38738670 | ||
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer | Q39401816 | ||
A robust immunohistochemical assay for detecting PTEN expression in human tumors | Q39646962 | ||
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias | Q40293372 | ||
A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer | Q40978920 | ||
Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion | Q42119481 | ||
PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy | Q43089446 | ||
Is PTEN loss associated with clinical outcome measures in human prostate cancer? | Q43249619 | ||
PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer | Q45251986 | ||
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer | Q47919199 | ||
TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. | Q51837762 | ||
Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer | Q57782669 | ||
Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer | Q57790298 | ||
PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications | Q57790325 | ||
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome | Q57790493 | ||
ThePTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion | Q63966367 | ||
Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer | Q87745893 | ||
P433 | issue | 8 | |
P921 | main subject | prostate cancer | Q181257 |
immunohistochemistry | Q899285 | ||
P304 | page(s) | 904-914 | |
P577 | publication date | 2016-05-13 | |
P1433 | published in | Modern Pathology | Q15724578 |
P1476 | title | Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. | |
P478 | volume | 29 |
Q36407003 | Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet. |
Q49964150 | Clinical Utility and Biologic Implications of Phosphatase and Tensin Homolog (PTEN) and ETS-related Gene (ERG) in Prostate Cancer |
Q49818398 | Clinical implications of PTEN loss in prostate cancer |
Q47129857 | Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer |
Q54964875 | Emerging biomarkers in the diagnosis of prostate cancer. |
Q93196102 | Emerging role of PTEN loss in evasion of the immune response to tumours |
Q90706115 | Everolimus inhibits the proliferation and migration of epidermal growth factor receptor-resistant lung cancer cells A549 via regulating the microRNA-4328/phosphatase and tensin homolog signaling pathway |
Q98945179 | High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts |
Q36192598 | MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study |
Q50133991 | Molecular Biomarkers in the Clinical Management of Prostate Cancer |
Q47877197 | PTEN allelic loss is an important mechanism in the late stage of development of oral leucoplakia into oral squamous cell carcinoma |
Q42371556 | PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort |
Q57049913 | PTEN status assessment in the Johns Hopkins active surveillance cohort |
Q64114534 | Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology |
Q90029848 | Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN) |
Q38967389 | Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers |
Q51586225 | TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer. |
Q90029873 | The Challenges of Optimizing Biomarkers To Guide Clinical Decision Making |
Q48228320 | Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. |
Q48231392 | Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections |
Q47908752 | Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial |
Q47231171 | p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer |
Search more.